...
首页> 外文期刊>Proteome science >Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection
【24h】

Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection

机译:根治性切除术后巨大肝细胞癌早期复发/转移的定量蛋白质组学分析

获取原文

摘要

Background Hepatic resection is the preferred treatment for huge hepatocellular carcinoma (>10 cm in diameter; H-HCC). However, the patients with H-HCC suffer from poor prognosis due to the early recurrence/metastasis. The underlying mechanism of H-HCC’s early recurrence/metastasis is currently not well understood. Results Here, we describe an Isobaric Tags for relative and absolute quantification (iTRAQ)-based quantitative proteomics approach to analyze the early recurrence/metastasis related proteins of H-HCC after radical resection through multidimensional chromatography coupled with tandem mass spectrometry (2DLC-MS/MS). The different protein expression profiles between the early recurrence/metastasis within 6 months(R/M≤6months) and late recurrence/metastasis within 6–12 months after surgery (R/M6-12months) were confirmed and might reveal different underlying molecular mechanisms. We identified 44 and 49 significantly differentially expressed proteins in the R/M≤6months group and the R/M6-12months group compared to the group who had no recurrence within 2 years post surgery (the NR/M group), respectively. Moreover, among those proteins, S100A12 and AMACR were down regulated in the R/M≤6months group but up-regulated in the R/M6-12months group; and this regulation was further confirmed in mRNA and protein level by Q-PCR, Western-Blot and Immunohistochemistry (IHC). Conclusions This current study presents the first proteomic profile of the early recurrence/metastasis of H-HCC. The results suggest that S100A12 and AMACR might be potential prognostic markers for predicting the early recurrence/metastasis of H-HCC after hepatectomy.
机译:背景肝切除术是巨大肝细胞癌(直径> 10 cm; H-HCC)的首选治疗方法。然而,由于早期复发/转移,患有H-HCC的患者预后较差。目前尚不清楚H-HCC早期复发/转移的潜在机制。结果在这里,我们描述了一种基于等压标记的相对和绝对定量(iTRAQ)定量蛋白质组学方法,用于通过多维色谱与串联质谱联用(2DLC-MS /多发性硬化症)。证实了术后6个月内早期复发/转移(R /M≤6个月)和术后6-12个月内晚期复发/转移(R / M6-12个月)之间的不同蛋白表达谱,可能揭示了不同的潜在分子机制。与在术后2年内未复发的组(NR / M组)相比,我们分别在R /M≤6个月组和R / M6-12个月组中鉴定出44种和49种显着差异表达的蛋白质。此外,在这些蛋白质中,R /M≤6个月组的S100A12和AMACR降低,而R / M6-12个月组的S100A12和AMACR升高。并且通过Q-PCR,Western-Blot和免疫组织化学(IHC)在mRNA和蛋白质水平上进一步证实了这种调节。结论本研究提供了H-HCC早期复发/转移的第一个蛋白质组学概况。结果表明,S100A12和AMACR可能是预测肝切除术后H-HCC早期复发/转移的潜在预后标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号